NASDAQ: KRRO · Life Sciences · 5 alerts · CIK 1703647
Share price
$12.71Close, Nov 16
Market cap
$174M
Shares outstanding
13.73MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Korro Bio, Inc. filings on SEC EDGAR ↗
Korro Bio Director Jean Francois Formela Sells $964K of Stock
Jean Francois Formela, Director, sold 66,015 shares of Korro Bio, Inc. at $14.30 to $15.60 a share (average $14.60) in 5 transactions, worth $964K in total between Nov 11, 2026 and Nov 12, 2026. Shares held after the trade: 121,219 (-5.4%).
Korro Bio received notice from Novo Nordisk of its election to terminate their 2024 research collaboration and license agreement for convenience, effective February 1, 2027. The partnership, which focused on cardiometabolic targets, had been paused since November 2025 and will now conclude with all licenses terminated and no milestone payments earned.
Counterparty
Novo Nordisk A/S
“Initiating dosing in ANCHOR brings KRRO-121 a meaningful step closer to these patients, and we look forward to dosing participants with UCDs in the first half of 2027. In AATD, our preclinical data showing over 95% correction of the disease-causing transcripts gives us confidence as we prepare KRRO-111 for the clinic. Both programs reflect what our OPERA platform is intended to do: correct disease at the level of RNA, with the precision to generate the protein of interest and convenience of subcutaneous administration. We are focused on execution, with two GalNAc-delivered RNA-editing programs advancing toward clinical data, and a cash runway into the second half of 2028.”
Ram Aiyar, PhD, MBA, Chief Executive Officer and President of Korro Bio
Korro Bio Insider Lynx1 Capital Management LP Buys $885K of Stock
Lynx1 Capital Management LP bought 79,809 shares of Korro Bio, Inc. at $9.68 to $12.11 a share (average $11.09) in 4 transactions, worth $885K in total between Oct 22, 2026 and Oct 26, 2026. Shares held after the trade: 1,624,789 (+1.6%).
Korro Bio announced positive preclinical results for KRRO-111, its RNA-editing development candidate for Alpha-1 Antitrypsin Deficiency (AATD). The studies demonstrated up to 95% mRNA editing and a 6-fold increase in total functional AAT protein, supporting a potential best-in-class profile for treating both lung and liver manifestations of the disease.
Korro Bio announced the dosing of the first cohort of participants in its ANCHOR Phase 1/2 clinical trial for KRRO-121, an RNA-editing oligonucleotide targeting hyperammonemia in patients with urea cycle disorders (UCD). The trial is currently enrolling healthy volunteers in Australia for safety and PK evaluation, with dosing in UCD patients expected to begin in the first half of 2027.
“Dosing the first cohort in ANCHOR is a step towards gaining evidence on safety first and then activity. Providing the potential for peace of mind for patients with a UCD, irrespective of their mutational background, is something we hope to demonstrate through this trial.”
Ram Aiyar, PhD, Chief Executive Officer and President of Korro